Daflon Dosage for Varicose Veins
For varicose veins and chronic venous insufficiency, the recommended dosage of Daflon 500 mg is 1000 mg daily (2 tablets of 500 mg), taken as a single daily dose. 1, 2
Standard Dosing Regimen
The FDA-approved dosing for Daflon (diosmiplex) is 1 tablet per day for chronic venous insufficiency manifested as varicose veins, spider veins, edema, stasis dermatitis, or venous ulcers. 1
Clinical studies have consistently used 1000 mg daily (2 tablets of 500 mg) as the standard therapeutic dose for varicose veins and venous insufficiency symptoms. 2, 3, 4
The medication should be taken once daily, which improves patient compliance and acceptance. 5
Timeline for Expected Results
For varicose veins and typical venous insufficiency symptoms (leg heaviness, swelling, pain), clinical improvement may not be evident for 4 to 8 weeks of continuous treatment. 1
For venous ulcers specifically, results may require several months of treatment before becoming apparent. 1
Clinical studies demonstrate that symptom improvement begins as early as 2 months, with approximately 50% of total symptom reduction achieved by this timepoint. 4
Clinical Efficacy Evidence
Daflon 500 mg at 1000 mg daily has demonstrated statistically significant improvement in functional symptoms, with reduction in supramalleolar circumference from 23.1 cm to 22.5 cm and calf circumference from 35.2 cm to 34.7 cm after 12 months of treatment. 4
The medication acts through multiple mechanisms: increasing venous tone, improving lymphatic drainage, protecting microcirculation, decreasing capillary hyperpermeability, and inhibiting inflammatory reactions. 2, 3
In long-term studies, overall efficacy was rated as excellent in 58% of patients and useful in 33% of patients after one year of continuous administration. 4
Safety Profile
Daflon 500 mg demonstrates excellent tolerability with minimal side effects, primarily limited to occasional gastralgia (reported in 7 out of 215 patients in one study). 4
Laboratory parameters remain stable during 12 months of continuous administration, confirming long-term safety. 4
Toxicological studies show no substance-related alterations regarding acute, subacute, or chronic toxicity, mutagenicity, fertility, or embryotoxicity. 5
Role in Treatment Algorithm
Daflon 500 mg serves as first-line pharmacological treatment for symptoms and edema of chronic venous insufficiency at any stage of disease. 2
The medication can be used as monotherapy in early-stage disease or in combination with compression therapy, sclerotherapy, or surgery in advanced stages. 2, 3
For patients where compression, sclerotherapy, or surgery are not indicated or not feasible, Daflon 500 mg provides an effective alternative treatment option. 2